### **SECTION 1: MEDICAID EXPENDITURES & ENROLLMENT**

1. Medicaid Expenditure Growth: FYs 2018-2020. For each year, indicate the annual percentage change in total Medicaid expenditures for each source of funds. (Exclude admin. and Medicare Part D Clawback payments.)

Fiscal Voor (generally, July 1 to June 20)	Percentage Change of Each Fund Source						
Fiscal Year (generally, July 1 to June 30)	Non-Federal Share*	Federal	Total: All Sources				
a. FY 2018 over FY 2017	%	%	%				
<b>b.</b> FY 2019 over FY 2018	%	%	%				
c. FY 2020 over FY 2019 (proj.)	%	%	%				

2	*Non-federal share inc		-					ral royonyos / gonora
	<b>Non-Federal Share.</b> Fo funds (vs. other state o			percentage of	the non-read	erai Sii	are is state gene	rai revenues / genera %
	Comments on non-fed							
	<b>Shortfall.</b> How likely is		•		given the fur	nding a	uthorizod?	
	Comments on Medicai			-	given the ful	iuiiig a	iutiiorizeur	<t< td=""></t<>
	Factors Driving Total E				most signific	ant fa	ctors that affect	ad growth or docling
	in <i>total</i> Medicaid spen	-	_		_		Clors that affect	ed growth of decline
		/ledicaid S	•		FY 2019		EV 202	0 (projected)
	<b>a.</b> Upward		: significant fact	or?	112013	<u></u>	11202	o (projected)
	Pressures		r significant fac					
	<b>b.</b> Downward		significant fact					
	Pressures		r significant fac					
	Comments on factors (			•			•	
	Change in Total Enroll			age changes i	n total Medic	aid (Ti	tle XIX - funded)	enrollment. (Exclude
	CHIP-funded enrollees	and fami	ly planning-on	ly enrollees).				
	Fiscal Year			Pe	rcentage Chan	ge in E	nrollment	
			All Enrollees	Children	Expansion A	dults	Aged/Disabled	All Other Adults
	<b>a.</b> FY 2019 over FY 201	18	%	%	%	)	%	%
	<b>b.</b> FY 2020 over FY 202		%	%			%	%
	Comments on enroll			lity group (Q	uestion 5): $\_$			
j.	Factors Driving Change							
а	<ul> <li>In the table below,</li> </ul>	•			•		at were upward	and downward
	pressures on total e	enrollmer	nt in FY 2019, a	ind expected	to be in FY 20	020.		
				FY 2019			FY 2020 (projec	ted)
	i. Upward Pressur							
	ii. Downward Pres			/6	6)			
	Comments on factors of	_		_				
	Per Enrollee Spending						on adults, aged/	disabled) growing
	faster or slower than o				briefly explai			
	ACA Medicaid Expansi	-				-	-	skip)
Г	Please identify the sou							
-			Expansion Non-					1
-	a. New Provider Tax			of Existing Prov	ider Tax/Fee	c		edicaid Expansion
L	<b>d.</b> State General Fur Comments on expansion		Other	۵۱.		f	Don't know	
	CONTINENTS ON EXPANSI	un midilici	ing (Question)	01.				
١ .	·				nt 12 manth	noriad	for which was he	rua data)
	Births Financed by Me  . What share of all bi	edicaid. (F	Respond with t	he most rece		period	for which you ho	ive data)

# SECTION 2: MEDICAID ELIGIBILITY STANDARDS, PREMIUMS, APPLICATION AND RENEWAL PROCESSES

1. Changes in Medicaid Eligibility Standards.\* Describe changes implemented in FY 2019 or adopted and likely to be implemented for FY 2020. (Exclude federally mandated and CHIP-funded changes and HCBS waiver slot increases or decreases.) Use the drop-down boxes to indicate the Year, Nature of Impact (Expansion, Restriction, or Neutral

effect from a beneficiary perspective) and waiver or SPA authority. Please do not include Section 1115 waiver changes if they have not yet been submitted to CMS. If no changes, check the box on line "d."

Nature of Eligibility Standards Change	State Fiscal Year	Elig. Group(s) Affected	Est.#of People Affected	Nature of Impact	Waiver or SPA
a.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>
b.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>
c.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>
<b>d.</b> No changes in either FY 2019	or FY 2020				

<sup>\*&</sup>quot;Eligibility standards" include income and asset limits, work/community engagement requirements, retroactive coverage, continuous eligibility, time limits, coverage lock-outs, treatment of asset transfers or income, or implementing buy-in options (including TWWIA or DRA).

Comments on changes in eligibility standards or waivers under development that are not yet pending at CMS:\_\_\_

- 2. Section 1115 Eligibility Waivers. If your state has implemented in FY 2019 or plans to implement in FY 2020 a Section 1115 waiver that includes eligibility conditions (e.g., work requirements, coverage lock-outs, premium requirements, etc.), please indicate whether implementation included or will include any of the following:
  - **a.** Increased administrative expenses due to systems changes *<choose one>* If so, please explain:
  - **b.** Increased admin. expenses due to staffing or contractor changes *<choose one>* If so, please explain:
  - **c.** MCO contract changes to add new MCO responsibilities *<choose one>* If yes, please briefly describe:
- 3. Changes in Monthly Contributions / Premiums. In the table below, please describe any monthly contribution / premium policy changes made in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority. Also indicate Effective Date and Eligibility Group(s) Affected. If there are no monthly contribution/premium changes to report for either year, check the box on line "d."

Monthly Contribution/Premium Action	Fiscal Year	Eff. Date	Elig. Group(s) Affected	Nature of Impact	Waiver or SPA					
a.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>					
b.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>					
c.	<choose one=""></choose>			<choose one=""></choose>	<choose one=""></choose>					
<b>d.</b> No changes in either FY 201	d. No changes in either FY 2019 or FY 2020									

Comments on premiums (Question 3): \_

- 4. Corrections-Related Enrollment Policies & Processes.
  - a. Please use the drop-downs to indicate whether your state is currently suspending or plans to implement suspensions of Medicaid eligibility for enrollees who become incarcerated in jails and/or prisons. Please include "suspension-like" policies (i.e., if Medicaid eligibility continues but benefit coverage is limited to inpatient hospitalizations).
     Jails: <choose one>

    Prisons: <choose one>
  - **b.** Do the corrections and Medicaid eligibility agencies have an electronic, automated data exchange process to facilitate suspension and reinstatement of enrollment for incarcerated individuals? *<choose one>*
  - c. As of October 2019, the SUPPORT Act prohibits states from terminating Medicaid eligibility for individuals under age 21 or former foster care youth up to age 26 while they are incarcerated and also requires states to redetermine eligibility for these populations prior to release without requiring a new application and restore coverage upon release. Please describe challenges or issues, if any, that your state is facing to come into compliance with these requirements:
  - **d.** Please describe any other changes to corrections-related enrollment policies in FY 2019 or FY 2020, including changes in outreach/assistance strategies to facilitate enrollment prior to release, Medicaid coverage for inpatient care provided to incarcerated individuals, etc.

Comments on corrections-related enrollment policies & processes (Question 4):

### **SECTION 3: PROVIDER PAYMENT RATES AND PROVIDER TAXES / ASSESSMENTS**

1. Fee-For-Service (FFS) Provider/MCO Payment Rates. Compared to the prior year, indicate by provider type any FFS rate changes implemented in FY 2019 or planned for FY 2020. Use "+" to denote an increase, "-" to denote a decrease, or "0" to denote "no change." (Include COLA or inflationary changes as "+".) Also, use the drop-downs to indicate requirements for MCO provider payments by provider type.

		FY	FY	Do MCO contracts:				
	Provider Type/MCO	2019	2020	Require payment changes that match uniform \$ or % changes made in FFS?	Mandate a minimum reimbursement rate floor?			
a.	Inpatient hospital*			<choose one=""></choose>	<choose one=""></choose>			
b.	Outpatient hospital			<choose one=""></choose>	<choose one=""></choose>			
c.	Doctors – primary care			<choose one=""></choose>	<choose one=""></choose>			
d.	Doctors – specialists			<choose one=""></choose>	<choose one=""></choose>			
e.	Dentists			<choose one=""></choose>	<choose one=""></choose>			
f.	MCOs (N/A if no MCOs)			N/A	N/A			
g.	Nursing Facilities*			<choose one=""></choose>	<choose one=""></choose>			
h.	HCBS			<choose one=""></choose>	<choose one=""></choose>			
				Explain any "varies" above	Explain any "varies" above			

<sup>\*</sup> For inpatient hospitals and nursing facilities, both "0" and "-" responses will be counted as rate restrictions in the budget survey report because unlike other provider groups, these providers typically receive routine cost-of-living adjustments.

Comments on provider/MCO payment rates (Question 1):

1000 Payment August 10 August 1

- **2. MCO Payment Arrangements.** As of July 1, 2019, does your state have one or more value-based purchasing State Directed Payment arrangements in place for MCOs? *<choose one>* If yes, please briefly describe: \_\_\_\_\_
- **3. Rural Payment Adjustments**. Please briefly describe any payment adjustments or enhancements in place for FY 2020 designed or intended to promote access to hospitals or other providers in rural areas:
- 4. Provider Taxes / Assessments.

**a.** Use the drop-downs to indicate state provider taxes in place in FY 2019, new taxes or changes for FY 2020, and the approximate size of the tax as a percentage of net patient revenues as of July 1, 2019.

	Provider Group In place in Subject to Tax FY 2019		Provider Tax Changes (New, Increased, Decreased, Eliminated, No Change, or N/A) in FY 2020	Size of tax as a percentage of net patient revenues (as of July 1, 2019)		
i.	Hospitals		<choose one=""></choose>	<choose one=""></choose>		
ii.	ICF/ID		<choose one=""></choose>	<choose one=""></choose>		
iii.	Nursing Facilities		<choose one=""></choose>	<choose one=""></choose>		
iv.	Other*:		<choose one=""></choose>	<choose one=""></choose>		
v.	Other*:		<choose one=""></choose>	<choose one=""></choose>		

<sup>\*&</sup>quot;Other" can include an MCO tax if specifically used to fund Medicaid. Exclude broad-based MCO taxes not dedicated to funding Medicaid.

b.	Does your state have in place or have plans to implement any provider taxes/assessments that are levied at the
	local level (cities, counties, hospital districts, etc.)? < choose one > If so, please describe:
Co	omments on provider taxes/assessments (Question 4):

- 5. Disproportionate Share Hospital (DSH) Payments.
  - a. Does your state intend to draw down its entire federal fiscal year 2019 DSH allotment?

<choose one>

**b.** If "no" to question a, please use the drop-down to indicate the primary reason for why your state does not plan to draw down the entire 2019 DSH allotment: *<choose one>* If "other," please describe:

### **SECTION 4A: BENEFIT, COST-SHARING, AND PHARMACY CHANGES**

 Benefit Actions. Describe benefits changes implemented during FY 2019 or planned for FY 2020. (Include changes in IMD coverage here and please specify whether the change is for patients with SUD, SMI/SED, or both. Exclude pharmacy benefit changes and HCBS benefit changes.)

Benefit Change	Fiscal Year	Eff. Date	Elig. Group(s) Affected	Nature of Impact
a.	<choose one=""></choose>			<choose one=""></choose>
b.	<choose one=""></choose>			<choose one=""></choose>
c.	<choose one=""></choose>			<choose one=""></choose>
d. No benefit changes (excluding HCBS and pha	rmacv) in either F\	2019 or FY 2	2020	

- **e.** Has or will your state adopt the new State Plan option for residential pediatric recovery centers for infants under age 1 with neonatal abstinence syndrome (NAS) and their families? <a href="choose one"><choose one</a>>
- f. Does your state cover or have plans to cover routine (not just medically necessary) HIV testing for traditional (non-ACA Medicaid expansion) populations? <choose one>

ents on benefit actions (Question 1):
---------------------------------------

down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority. Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."    Cost-Sharing Action   Fiscal Year   Eff. Date   Elig. Group(s)   Nature of Impact   Waiver or SPA     a.   < choose one>   < choose one>   < choose one>   < choose one>     c.   < choose one>   < choose one>   < choose one>   < choose one>     c.   < choose one>   < choose one>   < choose one>   < choose one>     d.   No changes in either FY 2019 or FY 2020     Comments on cost-sharing (Question 3):  4. Pharmacy Cost Drivers and Cost Control Challenges.   a. Please list the biggest cost drivers (excluding enrollment growth) that affected growth in total pharmacy spending (all funds) in FY 2019   and projected for FY 2020     b. Please briefly describe the biggest challenges your program faces in controlling pharmacy costs:     5. Pharmacy Cost Containment Policy Changes. Please indicate any new or expanded pharmacy program cost containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDLs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.    Pharmacy Cost Containment Policy Changes   FY 2019   FY 2020     New   Expanded   New   Expanded     a.		IMD Services.						
b. If your state plans to pursue a Section 1115 IMD SUD waiver instead of or in addition to using a SPA, explain why (e.g., are there limitations in the SUPPORT Act State Plan option that prompted the pursuit of a waiver)?  c. Will your state pursue a Section 1115 IMD waiver for services for individuals with SMI or SED?		a. Does your state plan to a	dopt the SUPPOF	RT Act State F	lan option (avail	able from :	10/1/2019 -	– 9/30/2023) to cover
(e.g., are there limitations in the SUPPORT Act State Plan option that prompted the pursuit of a waiver?]  c. Will your state pursue a Section 1115 IMD waiver for services for individuals with SMI or SED?  d. Did/will your state use the Medicaid managed care "in lieu of" authority for enrollees (ages 21-64) receiving inpatient treatment in an IMD (as detailed in the 2016 final rule) in FY 2019 or in FY 2020?  choose one> Comments on IMD Services (Question 2):  3. Changes in Cost-Sharing. Describe any cost-sharing policy changes in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority, Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."  Cost-Sharing Action  Fiscal Year  Eff. Date  Eff. Date  Eff. Date  Eff. Date  Eff. Cost-Sharing Action  Affected.  No changes in either FY 2019 or FY 2020  d. No changes in either FY 2019 or FY 2020  d. No changes in either FY 2019 or FY 2020  d. No changes in either FY 2019 or FY 2020  b. Please briefly describe the biggest cost drivers (excluding enrollment growth) that affected growth in total pharmacy spending (all funds) in FY 2019  and projected for FY 2020. (Please exclude routine updates, e.g., to PDIs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.  Pharmacy Cost Containment Policy Changes. Please indicate any new or expanded pharmacy program cost containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDIs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.  Pharmacy Cost Containment Policy Changes  Pharmacy Cost Containment Policy Changes Please indicate any new or expanded pharmacy program cost containment strategies in place in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDIs or State Maximum Allowable Cost programs		IMD services for nonelde	rly adults with at	least one SU	D for up to 30 da	ys in a 12-	month peri	od? <choose one=""></choose>
c. Will your state pursue a Section 1115 IMD waiver for services for individuals with SMI or SED?		<b>b.</b> If your state plans to purs	sue a Section 111	.5 IMD SUD w	vaiver instead of	or in addit	ion to using	a SPA, explain why
d. Did/will your state use the Medicaid managed care "in lieu of" authority for enrolless (ages 21-64) receiving inpatient treatment in an IMD (as detailed in the 2016 final rule) in FY 2019 or in FY 2020? <a href="choose one">choose one</a> Comments on IMD Services (Question 2):  3. Changes in Cost-Sharing. Describe any cost-sharing policy changes in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority. Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."    Cost-Sharing Action		(e.g., are there limitations	s in the SUPPORT	Act State Pla	an option that pr	ompted th	e pursuit of	f a waiver)?
inpatient treatment in an IMD (as detailed in the 2016 final rule) in FY 2019 or in FY 2020?   Comments on IMD Services (Question 2):  Changes in Cost-Sharing. Describe any cost-sharing policy changes in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority. Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."  Cost-Sharing Action   Fiscal Year   Eff. Date   Elig. Group(s)   Nature of Impact   Waiver or SPA    a.		c. Will your state pursue a S	ection 1115 IMD	waiver for s	ervices for indivi	duals with	SMI or SED	? <choose one=""></choose>
Comments on IMIO Services (Question 2):  3. Changes in Cost-Sharing. Describe any cost-sharing policy changes in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate vear, Nature of Impact, and Waiver or SPA Authority. Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."    Cost-Sharing Action   Fiscal Year   Eff. Date   Elig. Group(s)   Affected   A		d. Did/will your state use th	e Medicaid mana	aged care "in	lieu of" authorit	y for enroll	ees (ages 2	1-64) receiving
3. Changes in Cost-Sharing. Describe any cost-sharing policy changes in FY 2019 or planned for FY 2020. Use the drop-down boxes to indicate Year, Nature of Impact, and Waiver or SPA Authority. Indicate Effective Date and Eligibility Group(s) Affected. If there are no changes to report for either year, check the box on line "d."    Cost-Sharing Action		inpatient treatment in an	IMD (as detailed	in the 2016	final rule) in FY 2	019 or in F	Y 2020?	<choose one=""></choose>
Group(s) Affected. If there are no changes to report for either year, check the box on line "d."		Comments on IMD Services (	Question 2):					
Cost-Sharing Action   Fiscal Year   Eff. Date   Elig. Group(s)   Nature of Impact   Waiver or SPA	3.	Changes in Cost-Sharing. Des	cribe any cost-sh	naring policy	changes in FY 20:	19 or planr	ed for FY 2	020. Use the drop-
Cost-Sharing Action		down boxes to indicate Year,	Nature of Impac	t, and Waive	r or SPA Authorit	y. Indicate	Effective D	ate and Eligibility
a.		Group(s) Affected. If there are	e no changes to r	eport for eitl	her year, check t	ne box on l	ine "d."	
C.		Cost-Sharing Action	Fiscal Year	Eff. Date		Nature	of Impact	Waiver or SPA
C.	а	a.	<choose one=""></choose>			<choo< td=""><td>se one&gt;</td><td><choose one=""></choose></td></choo<>	se one>	<choose one=""></choose>
d.	k	o.	<choose one=""></choose>			<choo< td=""><td>se one&gt;</td><td><choose one=""></choose></td></choo<>	se one>	<choose one=""></choose>
Comments on cost-sharing (Question 3):  4. Pharmacy Cost Drivers and Cost Control Challenges.  a. Please list the biggest cost drivers (excluding enrollment growth) that affected growth in total pharmacy spending (all funds) in FY 2019	C	e	<choose one=""></choose>			<choo< td=""><td>se one&gt;</td><td><choose one=""></choose></td></choo<>	se one>	<choose one=""></choose>
a. Please list the biggest cost drivers (excluding enrollment growth) that affected growth in total pharmacy spending (all funds) in FY 2019	С							
a. Please list the biggest cost drivers (excluding enrollment growth) that affected growth in total pharmacy spending (all funds) in FY 2019		Comments on cost-sharing (C	(uestion 3):					
spending (all funds) in FY 2019 and projected for FY 2020  b. Please briefly describe the biggest challenges your program faces in controlling pharmacy costs:  5. Pharmacy Cost Containment Policy Changes. Please indicate any new or expanded pharmacy program cost containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDLs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.    Pharmacy Cost Containment Policy Changes	4.	Pharmacy Cost Drivers and C	ost Control Chall	lenges.				
b. Please briefly describe the biggest challenges your program faces in controlling pharmacy costs:  5. Pharmacy Cost Containment Policy Changes. Please indicate any new or expanded pharmacy program cost containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDLs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.  Pharmacy Cost Containment Policy Changes    FY 2019		a. Please list the biggest cos	t drivers (excludi	ing enrollmer	nt growth) that a	ffected gro	wth in tota	l pharmacy
5. Pharmacy Cost Containment Policy Changes. Please indicate any new or expanded pharmacy program cost containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDLs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.  Pharmacy Cost Containment Policy Changes    PY 2019   FY 2020     New   Expanded   New   Expanded     a.								
containment strategies implemented in FY 2019 or planned for FY 2020. (Please exclude routine updates, e.g., to PDLs or State Maximum Allowable Cost programs). Check the box on line "d" if there are no changes for either year.    Pharmacy Cost Containment Policy Changes		<b>b.</b> Please briefly describe the	e biggest challen	ges your pro	gram faces in cor	itrolling ph	armacy cos	ts:
Pharmacy Cost Containment Policy Changes    FY 2019	5.	<b>Pharmacy Cost Containment</b>	<b>Policy Changes.</b>	Please indica	ite any new or ex	panded ph	armacy pro	ogram cost
Pharmacy Cost Containment Policy Changes    New   Expanded   New   Expanded		containment strategies imple	mented in FY 20:	19 or planned	d for FY 2020. <i>(Pl</i>	ease exclu	de routine ι	ıpdates, e.g., to
New   Expanded   New   Expanded		PDLs or State Maximum Allow	vable Cost progra	<i>ams).</i> Check t	he box on line "d	I" if there a	re no chan	ges for either year.
a. b. c. d. No changes in either FY 2019 or FY 2020  Comments on pharmacy (Questions 4-5):  SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.  Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2019  Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2020 Changes FY 2020 Changes FY 2020 Changes Choose one>  c. Prior authorization based on clinical criteria d. Step therapy c. Prior authorization based on clinical criteria related to opioid use c. Prior authorization Review (e.g., provider profiling and education) g. Medicaid prescribers must query the PDMP before prescribing opioids* h. Other: c. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020  In place in FY 2020 Changes Comments (briefly describe changes)  c. Choose one> c. Prior authorization based on clinical criteria choose one> c. Prior authorization based on clinical criteria related to opioid use c. Choose one> c. Prior authorization deview (e.g., provider profiling and education) c. Choose one> c. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020		Pharmacy Cost Contain	ment Policy Chan	gos	FY 2019			FY 2020
b. c. d. No changes in either FY 2019 or FY 2020  Comments on pharmacy (Questions 4-5):  SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.  Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2020 Changes  FY 2020 Changes  FY 2020 Changes  Comments (briefly describe changes)  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020		- Harmacy Cost Contain	michier oney chang	Bes	New	Expanded	New	Expanded
c.  d. No changes in either FY 2019 or FY 2020  Comments on pharmacy (Questions 4-5):  SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.  Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2020 Changes  FY 2020 Changes  Comments (briefly describe changes)  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020						<u> </u>	<del>                                     </del>	
d. No changes in either FY 2019 or FY 2020  Comments on pharmacy (Questions 4-5):  SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.  Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2019  Comments (briefly describe changes)  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use f. Retrospective Drug Utilization Review (e.g., provider profiling and education) g. Medicaid prescribers must query the PDMP before prescribing opioids* h. Other: c. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	_							
Comments on pharmacy (Questions 4-5):  SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    In place   FY 2019	b	).						
SECTION 4B: OPIOID USE DISORDER PREVENTION, HARM REDUCTION, AND TREATMENT  1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    Needicaid FFS PBM Strategies to Address Opioid Misuse	b c	). 	40 FV 2020					
1. Pharmacy Benefit Management (PBM) Strategies. Please indicate whether your state had one or more of the listed strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020. (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    Medicaid FFS PBM Strategies to Address Opioid Misuse	b c	o. c. d. No changes in either FY 20						
strategies in place in FFS for non-MAT opioids in FY 2019 and use the drop-downs to indicate changes in FY 2020.  (Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    Medicaid FFS PBM Strategies to Address Opioid Misuse	c d	o. :. d. No changes in either FY 20 Comments on pharmacy (Que	estions 4-5):					
(Use "expanded/enhanced" to indicate expansions in policies, including restrictive policies (e.g., adding more or tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    In place in FY 2019	c d	o. d. No changes in either FY 20 Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD	estions 4-5): DER PREVENTION	-				
tighter quantity limits would count as a policy expansion).) Identify any point-of-service opioid safety edits in 1.h.    In place in FY 2019	c d	D.  I. No changes in either FY 20  Comments on pharmacy (Que  CTION 4B: OPIOID USE DISORD  Pharmacy Benefit Manageme	estions 4-5): DER PREVENTION ent (PBM) Strate	gies. Please i	ndicate whether	your state	had one o	
Medicaid FFS PBM Strategies to Address Opioid Misuse  In place in FY 2019  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  lin place in place in place in FY 2019  choose one>  Comments (briefly describe (changes)  choose one>  choose one>  choose one>  choose one>  choose one>  choose one>  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	D.  I. No changes in either FY 20 Comments on pharmacy (Que CTION 4B: OPIOID USE DISORE Pharmacy Benefit Manageme strategies in place in FFS for r	estions 4-5):  PER PREVENTION  ent (PBM) Strate  non-MAT opioids	egies. Please i in FY 2019 a	indicate whether	your state downs to i	had one or ndicate cha	nges in FY 2020.
Medicaid FFS PBM Strategies to Address Opioid Misuse  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t	estions 4-5):  PER PREVENTION  ent (PBM) Strate  non-MAT opioids  o indicate expans	egies. Please i in FY 2019 ar sions in polic	indicate whether nd use the drop- ies, including res	your state downs to in trictive pol	had one on ndicate cha icies (e.g., a	nges in FY 2020. adding more or
Medicaid FFS PBM Strategies to Address Opioid Misuse  a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t	estions 4-5):  PER PREVENTION  ent (PBM) Strate  non-MAT opioids  o indicate expans	egies. Please i in FY 2019 ar sions in polic	indicate whether nd use the drop- ies, including res	your state downs to in trictive pol	had one on ndicate cha icies (e.g., a	nges in FY 2020. adding more or
a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  l. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t	estions 4-5):  PER PREVENTION  ent (PBM) Strate  non-MAT opioids  o indicate expans	egies. Please i in FY 2019 ar sions in polic	indicate whether nd use the drop- ies, including res	your state downs to in trictive pol nt-of-service	had one or ndicate cha icies (e.g., a e opioid sa	nges in FY 2020. adding more or fety edits in 1.h. Comments
a. Adoption of opioid prescribing guidelines  b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  Choose one>  I. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would	estions 4-5):  DER PREVENTION  ent (PBM) Strate  non-MAT opioids o indicate expans  count as a policy	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place	had one on ndicate cha icies (e.g., a re opioid sa FY 2020	nges in FY 2020. adding more or fety edits in 1.h. Comments (briefly
b. Prospective Drug Utilization Review  c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	c d	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would	estions 4-5):  DER PREVENTION  ent (PBM) Strate  non-MAT opioids o indicate expans  count as a policy	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place in	had one on ndicate cha icies (e.g., a re opioid sa FY 2020	nges in FY 2020. adding more or fety edits in 1.h. Comments (briefly describe
c. Prior authorization based on clinical criteria  d. Step therapy  e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would of Medicaid FFS PBM St	estions 4-5):  DER PREVENTION  ent (PBM) Strate  non-MAT opioids  o indicate expans  count as a policy  rategies to Addres	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Change	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)
d. Step therapy <choose one="">   e. Drug lock-in programs with enrollment criteria related to opioid use <choose one="">   f. Retrospective Drug Utilization Review (e.g., provider profiling and education) <choose one="">   g. Medicaid prescribers must query the PDMP before prescribing opioids* <choose one="">   h. Other: <choose one="">   i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020</choose></choose></choose></choose></choose>	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would of Medicaid FFS PBM Str	estions 4-5):  DER PREVENTION  ent (PBM) Strate non-MAT opioids o indicate expans count as a policy  rategies to Addres	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)
e. Drug lock-in programs with enrollment criteria related to opioid use  f. Retrospective Drug Utilization Review (e.g., provider profiling and education)  g. Medicaid prescribers must query the PDMP before prescribing opioids*  h. Other:  Choose one>  choose one>  i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORE  Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM St  a. Adoption of opioid prescribin b. Prospective Drug Utilization F	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes <choose or<br=""><choose or<="" td=""><td>nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)</td></choose></choose>	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)
f. Retrospective Drug Utilization Review (e.g., provider profiling and education)	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD  Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM St  a. Adoption of opioid prescribin b. Prospective Drug Utilization f c. Prior authorization based on	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review	egies. Please in FY 2019 arsions in polic expansion).)	indicate whether nd use the drop- ies, including res Identify any poi	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes of <a href="#"><choose <a="" href="#" of=""><choose <a="" href="#" of=""><a href="#"><a href<="" td=""><td>nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)  ne&gt;</td></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></choose></a>	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)  ne>
g. Medicaid prescribers must query the PDMP before prescribing opioids*	SE(	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM Str  a. Adoption of opioid prescribin b. Prospective Drug Utilization F c. Prior authorization based on d. Step therapy	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review clinical criteria	egies. Please in FY 2019 and sions in police expansion).)	indicate whether nd use the drop- ies, including res Identify any poir	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate charicies (e.g., a se opioid sa FY 2020 Changes or <choose <choose="" <choose<="" or="" td=""><td>nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes) ne&gt; ne&gt;</td></choose>	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes) ne> ne>
h. Other:	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would of Medicaid FFS PBM Str  a. Adoption of opioid prescribin b. Prospective Drug Utilization I c. Prior authorization based on d. Step therapy e. Drug lock-in programs with e	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids to indicate expans count as a policy rategies to Addres ag guidelines Review clinical criteria	related to opic	indicate whether nd use the drop- ies, including res Identify any poir se	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate charicies (e.g., a re opioid sa FY 2020 Changes or <choose <="" or="" p=""> <choose <="" or="" p=""></choose></choose></choose></choose></choose></choose></choose></choose>	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes) ne> ne> ne>
i. No FFS PBM opioid harm reduction strategies in place in FY 2019 or changes planned for FY 2020	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM St  a. Adoption of opioid prescribin b. Prospective Drug Utilization I c. Prior authorization based on d. Step therapy e. Drug lock-in programs with e f. Retrospective Drug Utilization	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review clinical criteria n Review (e.g., pro	related to opicy vider profiling	indicate whether and use the drop- ies, including res Identify any poin se	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes of schoose of schoolse of school	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)  ne> ne> ne> ne>
	SE(	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM St  a. Adoption of opioid prescribin b. Prospective Drug Utilization f c. Prior authorization based on d. Step therapy e. Drug lock-in programs with e f. Retrospective Drug Utilization g. Medicaid prescribers must que	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review clinical criteria n Review (e.g., pro	related to opicy vider profiling	indicate whether and use the drop- ies, including res Identify any poin se	your state downs to in trictive pol nt-of-servic In place in	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes of schoose of schoole	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)  ne> ne> ne> ne> ne> ne>
· · · · · · · · · · · · · · · · · · ·	SEC 1.	Comments on pharmacy (Que CTION 4B: OPIOID USE DISORD Pharmacy Benefit Manageme strategies in place in FFS for r (Use "expanded/enhanced" t tighter quantity limits would e  Medicaid FFS PBM Str  a. Adoption of opioid prescribin b. Prospective Drug Utilization f c. Prior authorization based on d. Step therapy e. Drug lock-in programs with e f. Retrospective Drug Utilization g. Medicaid prescribers must qu h. Other:	estions 4-5):  DER PREVENTION ent (PBM) Strate non-MAT opioids o indicate expans count as a policy rategies to Addres ag guidelines Review clinical criteria n Review (e.g., pro	related to opic	indicate whether and use the drop- ies, including res Identify any poin ise  oid use and education) g opioids*	your state downs to in trictive pol nt-of-servic In place in FY 2019	had one or ndicate cha icies (e.g., a re opioid sa FY 2020 Changes of schoose of schoole	nges in FY 2020. adding more or fety edits in 1.h.  Comments (briefly describe changes)  ne> ne> ne> ne> ne> ne>

	j.	Is your state accessing or pl 2019 and 2020 for PDMP in		_							tes for providers
_		to access PDMP)?									<choose one=""></choose>
2.		anaged Care PBM Opioid Pol									
	a.	If your state uses MCOs to o		•	•				July 1	1, 2019	9, MCOs are
		required to follow the FFS P	PBM s	strate	egies described	in Qu	estion 1 abov	e:			<choose one=""></choose>
	b.	If "Yes, in part", please brie	fly de	escrib	e the notable F	FS/ma	anaged care p	oolicy differer	nces:		
	Co	mments on opioid PBM strat	egies	(Qu	estions 1-2):						
3.	Co	verage of Non-Opioid Pain M	/lana	geme	ent Alternatives	s. Doe	s your state o	over the follo	owing	benef	fits or services
		en provided for the treatme									
		wns to indicate whether the				-					•
	uo	wits to indicate whether the		lace	FY 2020	ictici	your state p	ians to make		Place	FY 2020
		Benefit/Service		19			Benefit/Se	rvice		'19	
		Agunungtura		7	Changes		Massagatha	ra m. /		7	Changes
<u> </u>	a.	Acupuncture		_	<choose one=""></choose>	b.	Massage the			=	<choose one=""></choose>
	c.	Chiropractic services	Ļ	_	<choose one=""></choose>	d.	Physical ther		<u> </u>		<choose one=""></choose>
<u> </u>	e.	Cognitive behavioral therapy	Ļ	_	<choose one=""></choose>	f.	OTC pain me	dications	Ļ		<choose one=""></choose>
	g.	Biofeedback	L		<choose one=""></choose>	h.	Other:		L		<choose one=""></choose>
		mments on non-opioid pain r		_	ent alternatives	(Que	stion 3):				
4.	Me	edication Assisted Treatment	t (M/	<b>λΤ)</b> .							
	a.	MAT Access Challenges. In	the t	able	below, please id	dentif	y any challen	ges related to	acce	ss to N	AAT for Medicaid
		enrollees in your state (sele	ct all	that	apply).						
		,			cess Challenge	s (Che	ck all that ar	(vlac			
i.	Г	Shortage of waivered provider		ii		-	er shortages		eimbu	rsemer	nt rates
iv	=	Lack of treatment resources for		v							oral therapy
		nts at all ASAM levels			ccepting cash pay		•	services for p	_		
vii	_	Lack of knowledge among pro	ovide				ed with SUD				ch preferred by
	_	mmunity of evidence-based bes			mong providers			some provide			
		ices for SUD treatment, including			ommunity			, , , , , , , , , , , , , , , , , , ,		<b>у о р о</b> о	
х.		Lack of access for pregnant wo		X		rihe).		xii. No M	AT acc	ess ch	allenges
Λ.	_	mments/additional details or						XIII IVO IVI	711 000	2033 611	unenges
	_	MAT Access Initiatives. Plea			_		– voc or policio	implomente	d in E	V 2010	) or planned for
	b.				•		•	•			•
		FY 2020 intended to addres			_	-		ing changes	to pna	armacy	y benefit
		management policies (e.g.,			•						
	c.	Methadone Coverage. Plea			•			•			
		used to treat opioid use dis								to add	coverage ahead
		of the SUPPORT Act require									<choose one=""></choose>
	d.	If your state has any concer	ns ab	out	or expects to fa	ce any	y challenges r	elated to con	nplyin	g with	the SUPPORT
		Act's MAT drug coverage re	quire	emer	it, please descri	be:					
	Со	mments on opioid medicatio	-								
					•						
SEC	TIC	N 5A: MEDICAID DELIVERY S	SYSTI	EM							
1.	Me	edicaid Managed Care Overv	iew.	Wha	t types of mana	ged c	are systems ۱	were in place	in you	ur stat	e's Medicaid
	pro	ogram as of July 1, 2019? (che	eck a	ll tha	t apply):						
	Ē	MCO PCCM - Primary C	are (	ase l	Management [	<b>□</b> РНР	(PIHP or PAH	HP) Chhei	r:		
	$\vdash$	<b>No</b> managed care programs			_		=	· —			
	L	- , ,	•		- ,			•			_
2.		<b>anaged Care Changes</b> . Has yo			_	-	•			•	
	ch	anges in FY 2020 (e.g., elimin	ating	PCC	M, adding PHP,	imple	menting MC	O contracts fo	or the	first ti	ime)?
3.	Ро	pulation. Please indicate the	appı	oxim	ate share of yo	ur tot	al Medicaid p	opulation sei	rved b	y eacl	n acute care
	de	livery system model listed in	the t	able	below, as of Ju	ly 1, 2	<b>019</b> . If possik	ole, please als	o indi	cate t	he share of each
		gibility group served by each				-	•				
		al eligibles and family plannir		-	-		- , ·	•	,,		

	Delivery System	Distribution of	Medicaid popula	ation as of July 1, 2019	e (Each column shou	ld sum to 100%)
		<b>Total Population</b>	Children	Expansion Adults	Aged & Disabled	All Other Adults
a.	MCOs					
b.	PCCM (managed FFS)					
c.	Traditional FFS					
	Total	100%	100%	100%	100%	100%

Comments on populations served (Question 3):

If your state does not have MCOs, skip Sections 5B-5C. See Section 7 for non-MCO quality strategy questions.

# SECTION 5B: GEOGRAPHIC SCOPE, ENROLLMENT, & BENEFITS – ACUTE CARE MCOS

•	<b>~</b> .					
1.	Ged	ogra	ındı	c S	cope	٩.

a. Were acute care MCOs operating statewide as of July 1, 2019?

<choose one>

**b.** If not, does your state have plans to expand to new regions in FY 2020?

<choose one>

2. Enrollment of Specified Non-Dual, Non-LTSS Groups. For geographic areas where MCOs operate, use the dropdowns in the table to indicate for each group whether enrollment in acute care MCOs is "always mandatory," "always voluntary," "varies," or the group is "always excluded" from MCOs as of July 1, 2019.

	Acute Care MCO Enrollment Policies for Specified Non-Dual, Non-LTSS* Populations							
a.	Pregnant women	<choose one=""></choose>	b.	Medically fragile/technology dependent children	<choose one=""></choose>			
c.	Foster children	<choose one=""></choose>	d.	Persons with a SMI or SED	<choose one=""></choose>			
e.	Persons with ID/DD	<choose one=""></choose>	f.	Persons with physical disabilities	<choose one=""></choose>			
g.	Seniors	<choose one=""></choose>						
	Au							

\*LTSS includes institutional care and HCBS for persons with an institutional level of care, including ID/DD specialty services.

h. Dual Eligibles. Briefly describe acute care MCO enrollment policies for full benefit Dual Eligibles: _	
i. LTSS Enrollees. Briefly describe acute care MCO enrollment policies for persons receiving LTSS:	
Comments on acute care MCO enrollment requirements (Question 2):	

3. New Populations.

a.	Did (or will) you enroll previously excluded groups in acute care MCOs in FY 2019 or FY 2020?	<choose one=""></choose>
b.	If yes, please identify the new populations and which year they were (or will be) added:	

	, ,	•		,	•	•	•	•
c.	If yes, please i	indicate wheth	er enrollme	nt is (or will be) ma	ndatory	y:		

- 4. Changes to MCO Enrollment Requirements.
  - a. Did (or will) any group shift from voluntary to mandatory MCO enrollment in FY 2019 or FY 2020? <choose one>
  - **b.** If yes, please identify the groups shifted and the fiscal year the change was or will be made: \_\_\_\_\_

5.	<b>Reducing Acute Care MCO Enrollment.</b> Did (or will) your state implement policy changes designed to reduce acute
	care MCO enrollment in FY 2019 or FY 2020? <choose one=""> If so, briefly describe the changes in each year:</choose>

6. MCO Coverage of Behavioral Health (BH) Benefits as of July 1, 2019. For beneficiaries enrolled in an MCO for acute care benefits, please indicate whether the following BH benefits are always carved-in (i.e., virtually all services are provided directly by the MCO or through MCO sub-contracts), always carved-out (i.e., services are provided by a PHP or via FFS, not by the MCO), or whether carve-in policies vary by geography or other factors.

Services		Always	Always	Varies by:		Comments	
		Carved-in	Carved-out	Geography	Other (describe)	Comments	
a.	Specialty outpatient mental health*						
b.	Inpatient mental health						
c.	Outpatient SUD						
d.	Inpatient SUD						

<sup>\*&</sup>quot;Specialty outpatient mental health" refers to services utilized by adults with Serious Mental Illness (SMI) and/or youth with Serious Emotional Disturbance (SED), often provided by specialty providers such as community mental health centers.

7. Did (or will) your state make any changes to how BH benefits are delivered under MCO contracts (i.e., carve in/out) in FY 2019 or in FY 2020? *<choose one>* If so, briefly describe the changes:

	MLR. Does your state require MCOs that do not romments on MLR (including clarification on "yes			•	•	<choose< th=""><th>one&gt;</th></choose<>	one>
	Jse of Contractual Mechanisms to Improve MCC		•		· · · · · · · · · · · · · · · · · · ·	e indicate w	hether
	our state included any of the following strategie	•			• •		
	o indicate any changes for FY 2020. (Please use "						
	estrictive policies. For example, a withhold perce	•			· · · · · · · · · · · · · · · · · · ·		, a
	Quality Initiatives	In Place FY 2019	FY 2020 Cha		Acute Care or	Comments	s:
á	Pay-for-performance/performance bonus or penalty		<choose o<="" td=""><td>ne&gt;</td><td><choose one=""></choose></td><td></td><td></td></choose>	ne>	<choose one=""></choose>		
I	Capitation withhold* (specify % in comment field)		<choose o<="" td=""><td>ne&gt;</td><td><choose one=""></choose></td><td></td><td></td></choose>	ne>	<choose one=""></choose>		
_	. Auto-assignment algorithm includes quality		<choose o<="" td=""><td>ne&gt;</td><td><choose one=""></choose></td><td></td><td></td></choose>	ne>	<choose one=""></choose>		
-	performance measures				4-1		
	Publicly available comparison data about MCOs		<choose o<="" td=""><td></td><td><choose one=""></choose></td><td></td><td></td></choose>		<choose one=""></choose>		
	Other:	<u> </u>	<choose o<="" td=""><td></td><td><choose one=""></choose></td><td><u> </u></td><td></td></choose>		<choose one=""></choose>	<u> </u>	
	Capitation withhold" is defined as money withheld that MC	_				. :	
	If your state employed any of the quality strateg					indicate wr	netner
tr	e related performance measures address one or		•				
	Performance Measure Focus A		-		_		
		atal/Birth ou		iii.	Value-Based Purc		
			ntable Events	vi.	Health Info Excha		
		al Health			Substance Use Dis	order	
		ealth/Telen	neaicine	xii.	Other (describe):		
_		/O	2).				
	omments on quality initiatives in MCO contracts	=			5. i		
	Performance Improvement Projects (PIPs). Does	-				us area (e.g.	.,
	nealth disparities, birth outcomes)? <choose one<="" td=""><td></td><td>•</td><td></td><td></td><td></td><td></td></choose>		•				
	Alternative Provider Payment Models (APMs). In	•					
a.	Set a target percentage of MCO provider paymo	ents that m	iust be made	thro	ugh APMs? < <i>choose</i>	one> It so,	please
	briefly indicate:						
	<ul><li>i. The target percentage:</li></ul>						
	ii. Any Health Care Payment Learning a			-	- , ,	;:	
	iii. If there are incentives or penalties for	or meeting	/failing to me	et th	ese requirements:	<choos< td=""><td>se one&gt;</td></choos<>	se one>
b.	Require MCOs to:						
	<ol> <li>Participate in a state-directed VB</li> </ol>	P initiative	(e.g., episode	of c	are or ACO)	<choose< td=""><td>e one&gt;</td></choose<>	e one>
	ii. Develop a VBP strategy within sta	ate-specifie	ed guidelines			<choose< td=""><td>e one&gt;</td></choose<>	e one>
	iii. If "yes" to "i" or "ii" above, please	e briefly de	scribe				
С	omments on APMs (Question 4):						
SECT	ION 5D: PRIMARY CARE CASE MANAGEMENT (F	PCCM)					
	PCCM Policy Changes. Did your state implement,		plan to imple	ment	. policy changes des	signed to <i>inc</i>	rease
	or <b>decrease</b> the number of enrollees served throu				, , , , , , , , , , , , , , , , , , , ,		
		/ 2020?	<choose one<="" td=""><td></td><td></td><td></td><td></td></choose>				
	If yes in either FY 2019 or FY 2020, please brid						
	ION 5E: LIMITED-BENEFIT PREPAID HEALTH PLA			-	mlagga inclinate to the	المامة ما	
	PHP Services. If your state contracted with at least	st one PHP	as of July 1, 2	U19,	piease indicate in ti	ie table belo	w the
9	ervices provided under PHP contracts:	. (6)					_
			all that apply)	1			
	<b>a.</b> Outpatient mental health <b>b</b> . Inpa	atient menta	ii nealth		c.   Outpatient SUI	treatment ע	1

Dental care

LTSS

e.

h. [

Vision care

Other

SECTION 5C: QUALITY & CONTRACT ADMINISTRATION FOR MCOS (INCLUDING MLTSS)

Inpatient SUD treatment

g. NEMT

2.	PHP Policy Changes. Did your state implement	•	plement, policy	changes de	esigned to <i>increase</i> or		
	<ul><li>decrease the number of enrollees served through</li><li>a. FY 2019? <choose one=""></choose></li><li>b.</li></ul>	ugn a PHP in: FY 2020? <i><choos< i=""></choos<></i>	0.000				
	c. If yes in either FY 2019 or FY 2020, please						
3	PHP Initiatives to Improve Quality of Care. If y	•		nuality strat	egies (HFDIS		
٦.	measures, withholds etc.) in its PHP contract(s		•		<u> </u>		
SE	CTION 6A: LONG-TERM SERVICES AND SUPPOR	TS (LTSS) REBALANCI	NG				
1.				community	- hased settings in FV		
	2019 or FY 2020, please indicate below all reba				basea seemigs iii i		
[	LTSS Rebalancing Tools/Methods	<u> </u>	•	FY 20	19 FY 2020		
	a. Section 1915(c) or Section 1115 HCBS Waiver (no	ew waiver adopted, mo	re slots added an	d $\square$			
•	filled, or more slots filled) <b>b.</b> Section 1915(i) HCBS State Plan Option (new SP.	A or more enrollees ser	ved)				
-	c. Section 1915(k) Community First Choice Option		•				
-	<b>d.</b> Rebalancing incentives built into managed care	•					
•	e. Close/down-size a state institution and transition	<del>-</del>					
	f. Other:						
Ī	Comments on rebalancing tools/methods includ	ing type of incentives	built into mana	ged care co	ntracts if applicable		
	e.g., blended NF/HCBS rate, etc.) (Question 1): _						
2.	Program of All-Inclusive Care for the Elderly (	PACE).					
	a. Did/will your state add one or more new P	ACE site(s) in FY 2019	or FY 2020?		<choose one=""></choose>		
	b. Did/will your state increase the number of	persons served thro	ugh PACE in FY 2	019 or FY 2	020? <choose one=""></choose>		
	Comments on PACE changes (Question 2):						
3.	Restrict Number Served in the Community. If	your state adopted, o	or plans to adopt	t, new restri	ictions on the number		
	of people served in the community (e.g., elimin	nating a PACE site, re	ducing or newly	capping HC	BS waiver		
	enrollment) in FY 2019 or FY 2020, please brief	fly describe and speci	fy fiscal year:				
4.	LTSS Direct Care Workforce. Please indicate if	your state has or will	implement any	of the follo	wing Medicaid		
	initiatives in FY 2019 or FY 2020 to address LTS	S direct care workfor	ce shortages and	d/or turnov	er.		
	a. Wage Increase:				<choose one=""></choose>		
	<b>b.</b> Workforce Development (e.g., recruiting, t	raining, credentialing	;): FY 2019 <i><choo< i=""></choo<></i>	se one>; FY	2020 <choose one=""></choose>		
	c. Other (please specify year)						
5.	Housing Supports.						
	a. Please use the table below to describe any	_					
	waiver, or Section 1115 waiver to promote				bilities, seniors in		
	need of LTSS, individuals experiencing hon	nelessness, or individu	uals with SMI/SU				
	Services (please describe)	Target Population	Authority	In Place FY 2019?	FY 2020 Changes		
	i.		<choose one=""></choose>		<choose one=""></choose>		
	ii.		<choose one=""></choose>	<u> </u>	<choose one=""></choose>		
	iii.	2040	<choose one=""></choose>		<choose one=""></choose>		
	iv. No housing-related services in place in FY			+ f			
	<b>b.</b> If your state participated in the MFP progr	•	nausteu its gran	t lunding:	<choose one=""></choose>		
	i. If not, when are funds expected to	·	to the evaluation	on of the M	ED program.		
CE	c. List any services/admin activities your state will discontinue due to the expiration of the MFP program:  SECTION 6B: MANAGED LONG-TERM SERVICES AND SUPPORTS (MLTSS)						
	As of July 1, 2019, does your state cover long-t	•		ough any of	the following		
Τ.	managed care (capitated or managed fee-for-s	•			the following		
					Modicaid LTCC)		
	Medicaid MCO (MCO covers Medicaid acut Managed fee-for-service (PCCM entity or o	-	No MLTSS	overs only i	Medicaid LTSS)		
	If your state does not have MLTSS as of July 1.	•		low in thic	section		

2.	ML	TSS Ber	nefits.				
	a.	As of J	uly 1, 2019, were both institutional and HCBS serv	ices covered under an M	ILTSS contract?	<choose one=""></choose>	
3.	Geographic Scope.						
	a.	Were I	MLTSS plans operating in all regions of your state a	as of July 1, 2019?		<choose one=""></choose>	
	b.	If not,	did your state expand to new regions in FY 2019 o	r does it plan to do so in	FY 2020?	<choose one=""></choose>	
			on arrangements, benefits, or geographic scope of				
4.			ns Covered. For geographic areas where MLTSS op			to indicate if	
	-		t into MLTSS plans for each of the groups listed is '		•		
			ccluded" as of July 1, 2019. You may provide addition				
		-	but is mandatory in the counties where the progra			-	
			MLTSS Enrollment Policies for Specified			,	
			·	Duals	Non-Dual	s	
		<b>a.</b> S	eniors	<choose one=""></choose>	<choose on<="" th=""><th>e&gt;</th></choose>	e>	
		<b>b.</b> P	ersons with physical disabilities	<choose one=""></choose>	<choose on<="" th=""><th>e&gt;</th></choose>	e>	
			ersons with ID/DD	<choose one=""></choose>	<choose on<="" th=""><th>e&gt;</th></choose>	e>	
		<b>d.</b> №	Nedically fragile/technology dependent children	<choose one=""></choose>	<choose on<="" th=""><th>e&gt;</th></choose>	e>	
			ersons with a SMI or SED	<choose one=""></choose>	<choose on<="" th=""><th>e&gt;</th></choose>	e>	
	Cor	nments	s on populations covered under MLTSS (Question $^{\prime}$	1):			
5.	Ne	w Pop	ulations.				
		-	r will) you enroll previously excluded populations i			<choose one=""></choose>	
	b.	If yes,	please identify the new populations and which year	ar they were added:			
	c.	If yes,	please indicate whether enrollment is (or will be)	mandatory:			
6.	M	edicare	-Medicaid Integrated Care.				
	a.	<u>Financ</u>	<u>ial Alignment Initiative (FAI)</u> . As of July 1, 2019, do	es your state offer an FA	al demonstration	for dual	
		eligible	e individuals?			<choose one=""></choose>	
		i.	If "yes," will your state seek an extension beyond	d the end of the demons	tration?	<choose one=""></choose>	
			<ul> <li>A. Will the extension include a geograp</li> </ul>	hic expansion?		<choose one=""></choose>	
		ii.	If "no," will your state apply for a capitated FAI,	a managed fee-for-servi	ce FAI, or a new s	state-developed	
			model?			<choose one=""></choose>	
	b.	D-SNP:	s/FIDE Plans. As of July 1, 2019:				
		i.	Does your state contract with dual eligible specia	al needs plans (D-SNPs)?		<choose one=""></choose>	
		ii.	Does your state require MLTSS plans to also offe	r dual eligible special ne	eds plans (D-SNF	s) or Fully	
			Integrated Dual Eligible (FIDE) plans?			<choose one=""></choose>	
		iii.	Has your state applied for "default enrollment" i	nto integrated D-SNPs o	r FIDE plans (wh	en Medicaid	
			enrollees first become Medicare eligible)?	-		<choose one=""></choose>	
	Со	mment	ts on Medicare-Medicaid Integrated Care (Questio	n 6):			
7.			<b>Enrollees Served</b> . If your state implemented or pl		changes designe	ed to <i>decrease</i>	
	-الـ		A STATE OF THE STA				

the number of enrollees served in MLTSS plans in FY 2019 or FY 2020, please briefly describe the changes: \_

### **SECTION 7: MEDICAID DELIVERY SYSTEM AND PAYMENT REFORMS**

1. Please indicate in the table below delivery system and payment reform initiatives (including multi-payer initiatives that Medicaid is a part of) in place in FY 2019. Use the drop-downs to indicate changes to these initiatives in FY 2020. Use the "Additional Information" column to describe the initiatives or provide a web link for more info.

	Total occurrence in the manifestal internation condition to describe	In Place	Changes in	Additional Information: (specify
	Delivery System and Payment Reform Initiatives	FY 2019	FY 2020:	if part of multi-payer initiative)
a.	Patient-Centered Medical Home		<choose one=""></choose>	
b.	Health Home (under ACA Section 2703)		<choose one=""></choose>	
c.	Accountable Care Organization		<choose one=""></choose>	
d.	Episode of Care Payments		<choose one=""></choose>	
e.	Delivery System Reform Incentive Payment (DSRIP) Waiver		<choose one=""></choose>	
f.	All-Payer Claims Database		<choose one=""></choose>	
g.	Other:		<choose one=""></choose>	

	<b>h.</b> As of July 1, 2019, has your state requested or received approval, or do you		
	enhanced match rate for two additional quarters (i.e., for a total of 10 quar	•	
	approved on or after October 1, 2018, as permitted under the SUPPORT Act	t?	<choose one=""></choose>
	Comments on delivery system and payment reforms (Question 1):		
2.	SUD/Opioids Initiatives. Did your state submit an application to pursue the following		grams:
	CMMI SUD/Opioids Initiatives (Check all that apply)		
	<b>a</b> . The Maternal Opioid Misuse (MOM) Model <b>b.</b> Integrated Care for Kids	(InCK) Model	
	Comments (Question 2):		
3.		· · ·	
	(HEDIS <sup>©</sup> measures, bonuses, withholds, etc.) in its FFS delivery system (which m	ay include PCCMs	, ASO
	arrangements etc.) in FY 2019 or FY 2020, please describe.		
4.	Other Medicaid Initiatives. If your state has or will implement an initiative in eigenvalue.	ther of the areas I	isted below in FY
	2019 or FY 2020, please briefly describe.		
	<ul> <li>a. Initiative(s) to improve birth outcomes/address maternal mortality challenges.</li> </ul>	_	
	<b>b.</b> Initiative(s) to support employment without imposing a work requirement		
	Comments on "Other" Medicaid Initiatives (including any challenges or opportur	nities experienced	so far):
SFC	CTION 8: SOCIAL DETERMINANTS OF HEALTH (SDH)		
			CO initiatives
L.	<b>Policies.</b> Please indicate whether the policies listed below are MCO requirements		
		Requirement in MCO Contracts	Non-MCO Initiative
а	Screen enrollees for social needs (e.g., housing services, SNAP)?	<pre><choose one=""></choose></pre>	<choose one=""></choose>
b		<choose one=""></choose>	<choose one=""></choose>
C		<choose one=""></choose>	<choose one=""></choose>
d		<choose one=""></choose>	<choose one=""></choose>
e		<choose one=""></choose>	<choose one=""></choose>
f.		<choose one=""></choose>	<choose one=""></choose>
_	mments on SDH requirements/initiatives (Question 1):		
	Corrections-Related Populations. Are care coordination services provided to enr	ollees prior to rele	ease from
	incarceration through FFS: <i><choose one=""></choose></i> and/or are MCOs required to provide s		
	either, briefly describe including types of services (e.g., prescription drugs and M		•
SEC	CTION 9: ADMINISTRATION AND FUTURE OUTLOOK FOR THE MEDICAID PROGRA	M	
L.	Block Grant Waiver. CMS is developing guidance about block grant waivers / cap	pped federal finan	cing. Do you
	think your state would be interested in pursuing such a model?		
2.	Preparing for Future Program Pressures. Please describe initiatives or plans to b	etter prepare you	r state for an
	aging population or plans to prepare for a potential economic downturn or reces	ssion	
3.	Immigration. Please briefly describe any notable Medicaid enrollment and/or or	service utilization	changes for
	immigrant populations (including related to citizen children of immigrant familie	s) in FY 2019 or an	ticipated for FY
	2020 if known. Enrollment changes: Service utilization changes:	<u></u>	
1.	ACA Medicaid Expansion. Please describe the likelihood of future changes relate	ed to the ACA Med	licaid expansion in
	your state		
5.	Federal / State Coverage Expansion Proposals. What do you see as the top two	or three potential	challenges or
	opportunities for your state Medicaid program related to proposed federal or sta	ate-level coverage	expansions such
	as Medicare-for-all, public plan options and Medicaid Buy-in options?		
5.	Conclusions/Outlook.		
	a. What do you see as the top priorities for your state's Medicaid program over	the next year or	so?
	<b>b.</b> When you step back and look at your Medicaid program, what is it that you to	take the most prid	e in about
	Medicaid in your state — considering things such as Medicaid's impact in the	community and l	nealth care
	insurance market, administration, new policies or initiatives?	-	